Study identifier:D7913C00070
ClinicalTrials.gov identifier:NCT01785888
EudraCT identifier:N/A
CTIS identifier:N/A
A diagnostic Study of European and Japanese advanced NSCLC patients to evaluate suitable sample types for EGFR testing,
EGFR mutation status in aNSCLC patients (locally advanced and/or metastatic disease) with adenocarcinoma and non-adenocarcinoma histologies.
N/A
No
-
All
1311
Observational
18 Years - 99 Years
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Sept 2016 by AstraZeneca
AstraZeneca
-
This is a non-interventional diagnostic, international, multicenter and non-comparative study of EGFR mutation status in aNSCLC patients (locally advanced and/or metastatic disease) with adenocarcinoma and non-adenocarcinoma histologies. This study will be conducted in Japan and Europe and will assess the concordance of EGFR mutation status derived from tumour samples and blood based circulating free DNA. The data generated will inform the use of less-invasive sample types in diagnostic practice. The study also aims to assess the current status of EGFR mutation testing across Japan and Europe and gaps in currently available data including EGFR mutation frequency in particular populations and demographic subgroups, EGFR mutation frequency in histological subtypes of NSCLC, EGFR mutation test process and methodology, utility of multiple sample types in the assessment of EGFR mutation status, and impact of EGFR mutation status on therapy choice. The data may be used to drive improvements to the EGFR mutation testing process, ensuring that patients have access to testing and are treated appropriately on the basis of the molecular features of their disease.
A diagnostic Study of European and Japanese advanced NSCLC patients to evaluate suitable sample types for EGFR testing,
Location
Location
's Hertogenbosch, Netherlands
Location
Nieuwegein, Netherlands
Location
Breda, Netherlands
Location
Bergen op Zoom, Netherlands
Location
Arnhem, Netherlands
Location
Rotterdam, Netherlands
Location
Saint-Quentin, France
Location
Saint-Brieuc, France
Arms | Assigned Interventions |
---|---|
Locally advanced/metastatic NSCLC pts. Patients(pts.) with locally advanced (stage IIIA/B) or metastatic NSCLC who have not received any local or systemic chemotherapy, and are not eligible for curative treatment (including surgery and chemoradiotherapy) | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.